Acute renal failure after myeloablative hematopoietic cell transplant: Incidence and risk factors

Kidney International

Volumn 67, Issue 1, 2005, Pages 272-277

  Hingorani, Sangeeta R ^a   Guthrie, Katherine ^b   Batchelder, Ami ^b   Schoch, Gary ^b   Aboulhosn, Nada ^b   Manchion, Janel ^b   McDonald, George B ^b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Acute renal failure; Hematopoietic cell transplant; Myeloablative conditioning therapy; Risk factors

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIHYPERTENSIVE AGENT; CREATININE; CYCLOPHOSPHAMIDE; DIURETIC AGENT; GENTAMICIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW PURGING; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEPSIS;

EID: 10944233521     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00078.x     Document Type: Article

References (38)

1. GRUSS E, BERNIS C, TOMAS JF, et al: Acute renal failure in patients following bone marrow transplantation: Prevalence, risk factors and outcome. Am J Nephrol 15:473-479, 1995
2. ZAOER RA, O'QUIGLEY J, ZAGER B, et al: Acute renal failure following bone marrow transplantation: A retrospective study of 272 patients. Am J Kidney Dis 13:210-216, 1989
3. LANE PH, MAUER SM, BLAZAR BR, et al: Outcome of dialysis for acute renal failure in pediatric bone marrow transplant patients. Bone Marrow Transplant 13:613-617, 1994
4. PARIKH CR, MCSWEENEY PA, KORULAR D, et al: Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 62:566-573, 2002
5. VAN WHY S, FRIEDMAN A, WEI L, et al: Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant 7:383-388, 1991
6. MOHRMANN M, ANSORGE S, SCHMICH U, et al: Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatr Nephrol 8:157-163, 1994
7. MCDONALD GB, SLATTERY JT, BOUVIER ME, et al: Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101:2043-2048, 2003
8. BONILLA-FELIX M, YETMAN R, PORTMAN R: Epidemiology of hypertension, in Pediatric Nephrology, edited by Barrett T, Avner E, Harmon W, Baltimore, Lippincott, Williams & Wilkins, 1999, pp 959-985
9. DELEVE LD, SHULMAN HM, MCDONALD GB: Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (venocclusive disease). Semin Liver Dis 22:27-41, 2002
10. MCDONALD GB, HINDS MS, FISHER LB, et al: Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118:255-267, 1993
11. PRZEPIORKA D, WEISDORF D, MARTIN P, et al: 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828, 1995
12. ATKINSON K, DOWNS K, ASHBY M: Clinical correlations with blood levels after allogeneic bone marrow transplantation: An analysis of four different assays. Transplant Proceedings 22:1331-1334, 1990
13. KIST-VAN HOLTHE J, GOEDVOLK CA, BRAND R, et al: Prospective study of renal insufficiency after bone marrow transplantation. Pediatr Nephrol 17:1032-1037, 2002
14. ZAGER RA, ANDOH T, BENNETT W: Renal cholesterol accumulation: A durable response after acute and subacute renal insults. Am J Pathol 159:743-752, 2001
15. ZAGER RA, SHAH V, SHAH H, et al: The mevalonate pathway during acute tubular injury. Am J Pathol 161:681-692, 2002
16. KIST-VAN HOLTHE J, VAN ZWET J, BRAND R, et al: Bone marrow transplantation in children: Consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant 22:559-564, 1998
17. FINK J, COOPER M, BURKHART K, et al: Marked enzymuria following bone marrow transplantation: A correlate of veno-occlusive disease-induced 'hepatorenal syndrome.' J Am Soc Nephrol 6:1655-1660, 1995
18. MICHAEL M, KUEHNLE I, GOLDSTEIN S: Fluid overload and acute renal failure in pediatric stem cell transplant patients. Pediatr Nephrol 19:91-95, 2004
19. FUGE R, BIRD J, FRASER A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Hematol 113:58-64, 2001
20. PAQUETTE R, TRAN L, LANDAW E: Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 22:351-357, 1998
21. UDERZO C, FUMAGALLI M, DE LORENZO P, et al: Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant 26:1005-1009, 2000
22. LONNERHOLM G, CARLSON K, BRATTEBY L, et al: Renal function after autologous bone marrow transplantation. Bone Marrow Transplant 8:129-134, 1991
23. MARSHALL R, SWENY P: Haemolytic-uraemic syndrome in recipients of bone marrow transplants not treated with cyclosporin A. Histopathology 10:953-962, 1986
24. ANTIGNAC C, GUBLER M-C, LEVERGER G, et al: Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 35:1336-1344, 1989
25. SCHRIBER J, HERZIG G: Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 42:126-133, 1997
26. ATKINSON K, BIGGS J, HAYES J, et al: Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: Three distinct syndromes. Br J Hematol 54:59-67, 1983
27. ZEIGLER Z, ROSENFELD C, ANDREWS D III, et al: Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 52:213-220, 1996
28. CHAPPELL M, KEELING D, PRENTICE H, et al: Haemolytic uraemic syndrome after bone marrow transplantation: An adverse effect of total body irradiation? Bone Marrow Transplant 3:339-347, 1988
29. COHEN E, LAWTON C, MOULDER J: Bone marrow transplant nephropathy: Radiation nephritis revisited. Nephron 70:217-222, 1995
30. BUTLER W, BENNETT J, ALLING D: Nephrotoxicity of amphotericin B, early and late effects in 81 patients. Ann Int Med 61:175-187, 1964
31. HARBARTH S, BURKE J, LLOYD J, et al: Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:120-127, 2002
32. BATES D, Su L, Yu D, et al: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-693, 2001
33. WINGARD J, KUBILIS PS, LEE L, et al: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402-1407, 1999
34. WALSH T, FINBERG R, ARNDT C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764-771, 1999
35. PRENTICE H, HANN I, HERBRECHT R, et al: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Hematol 98:711-718, 1997
36. CAGNONI PJ: Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 49:81-86, 2002
37. SORKINE P, NAGAR H, WEINBROUM A, et al: Administration of amphotericin B in lipid emulsion decreases nephrotoxicity. Crit Care Med 24:1311-1315, 1996
38. MARR K: Empirical antifungal therapy: New options, new tradeoffs. N Engl J Med 346:278-280, 2002